National Colorectal Cancer Roundtable (NCCR) aims to increase screening rates to 80% by 2018

Increasing colorectal cancer screening rates to 80% by 2018 would prevent an additional 21,000 colorectal cancer deaths per year by 2030, according to a new study published in CANCER (2015; doi:10.1002/cncr.29336).

The study is the first to estimate the public health benefits of increasing screening rates to "80% by 2018." This is a recent initiative from the National Colorectal Cancer Roundtable (NCCRT), a national coalition of public, private, and voluntary organizations that aims for screening rates of 80% in the United States by 2018. The study was co-authored by American Cancer Society epidemiologist Ahmedin Jemal, DVM, PhD.

Colorectal cancer is the third leading cause of cancer death in both men and women in the United States, and the second leading cause for both sexes combined. An estimated 132,700 new cases and 49,700 deaths are expected in 2015 in the United States. Data from the past decade show that both incidence and mortality from colon cancer are decreasing at a rate of approximately 3% per year, largely due to the increased use of screening. Still, fewer than 6 in 10 US adults (58%) ages 50 to 75 years underwent guideline-recommended testing in 2013.

Studies indicate lack of screening is responsible for a substantial percentage of colorectal cancer deaths, which led to the launch of NCCR's "80% by 2018" campaign. The current study was designed to measure the potential benefits of increasing uptake by an additional 22% in terms of the number of colorectal cancer cases and deaths.

Researchers led by Reinier G. S. Meester, MS, at Erasmus MC University Medical Center in Rotterdam, the Netherlands, used a computer model to show the effects of increasing screening rates from approximately 58% in 2013 to 80% in 2018 compared to a scenario in which the screening rate remained approximately constant.

They found increasing screening rates to 80% by 2018 would reduce projected colorectal cancer incidence rates by 17% and mortality rates by 19% during short-term follow-up (2013 through 2020) and by 22% and 33%, respectively, during extended follow-up (2013 through 2030). Those reductions would amount to a total of 277,000 averted new cancers and 203,000 averted colorectal cancer deaths from 2013 through 2030.

The authors concluded increasing the uptake of colorectal cancer screening in the United States to 80% by 2018 could have a considerable and escalating public health impact.

"The barriers to increasing colorectal cancer screening in the United States are significant and numerous," said Richard C. Wender, MD, chief cancer control officer and chair of the National Colorectal Cancer Roundtable. "But this study shows that investing in efforts to clear these hurdles will result in a major cancer prevention success."

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs